# Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

> **NCT02233504** · EARLY_PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 25 (estimated)

## Conditions studied

- High Risk MDS or AML Patients

## Interventions

- **DRUG:** Exjade® (deferasirox, ICL670)

## Key facts

- **NCT ID:** NCT02233504
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2017-10
- **Final completion:** 2017-10-02
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02233504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02233504, "Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02233504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*